Last reviewed · How we verify
HRS-7058
At a glance
| Generic name | HRS-7058 |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors (PHASE2)
- A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour (PHASE2)
- A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-7058 CI brief — competitive landscape report
- HRS-7058 updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI